cket No.: WWELL73.007AUS

Customer No. 20,995

INFORMATION DISCLOSURE STATEMENT

Applicant

Lang et al.

App. No

10/687,523

Filed

October 15, 2003

For

CICKb MUTATION AS A

DIAGNOSTIC AND

THERAPEUTICAL TARGET

Examiner

Carlson, Karen C.

Art Unit

1653

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 11 references to be considered by the Examiner. Also enclosed are 11 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

06/24/2005 AKELECH1 00000007 10687523

.

Respectfully submitted,

01 FC:1806

180.00 OP

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 20, 2005

By:

Marina L. Gordey

Registration No. 52,950

Agent of Record

Customer No. 20,995

(805) 547-5580

1614530:vr 041505

INFORMATION DISCLOSURE
TEMENT BY APPLICANT

	Application No.	10/687,523
	Filing Date	October 15, 2003
	First Named Inventor	Lang et al.
	Art Unit	1653
	Examiner	Carlson, Karen C.
	Attorney Docket No.	WWELL73.007AUS

<u> </u>
(Multiple sheets used when necessary)
SHEET 1 OF 1

	U.S. PATENT DOCUMENTS					
Examiner Initials	Number - Kind Code lit known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	1	WO 99/16909 A1	04-08-1999	Yale University		
	2	WO 01/73128 A1	10-04-2001	DZ-Genes, LLC		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Ci Initials No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	3	JECK, N. et al. (2003) "Functional importance of CLCNKB genetics variants" Pediatric Nephrology, 18:13C, XP002314407.				
	4	JECK, N. et al. (2003) "A common sequence variation of the CLCNKB gene strongly activates CLC-KB chloride channel activity (W22)" Nephrology Dialysis Transplantation Oxford 18:555, XP002314408.				
	5	JECK, N. et al. (2004) "Activating mutation of the renal epithelial chloride channel CLC-KB predisposing to hypertension" Hypertension, 43:1175-1181.				
	6	KIEFERLE, S. et al. (1994) "Two highly homologous members of the CIC chloride channel family in both rat and human kidney" PNAS USA 91:6943-6947.				
	7	KONRAD, M. et al. (2000) "Mutations in the chloride channel gene CLCNKB as a cause of classic barter syndrome" J. Am. Soc. Nephrol. 11:1449-1459.				
	8	SIMON, D.B. et al. (1999) "Homo sapiens chloride channel Kb (CLCNKB) mRNA" DATABASE GENEBANK (1999) "Online! NCBI: XP002314410.				
	9	SIMON, D.B. et al. (1997) "Mutations in the chloride channel gene, CLCNKB, cause bartter's syndrome type III" Nature Genetics 17:171-178.				
	10	International Search Report from co-pending application PCT/EP2004/011192.				
	11	Written Opinion from co-pending application PCT/EP2004/011192.				

1614486:vr 041505

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.